BIOMAT Database Logo BIOMAT Database Logo

Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases. 1995

T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
University of British Columbia Pulmonary Research Laboratory, St. Paul's Hospital, Vancouver.

The tachykinin neuropeptides substance P and neurokinin (NK) A have been postulated to participate in the inflammatory reaction in airways of smokers and asthmatics. We have examined the hypothesis that the expression of one or more of the three cloned tachykinin receptors (NK1, NK2, and NK3) is increased in inflammatory airway disorders, which could result in augmentation of the effect of released tachykinin neuropeptides. NK1 receptor and NK2 receptor but not NK3-receptor mRNA were detected by ribonuclease protection assay in RNA from both cartilaginous and membranous bronchi and subpleural lung. In lung samples containing membranous airways, NK2-receptor mRNA expression was increased fourfold in asthmatics compared with nonsmoking controls, whereas NK1-receptor mRNA levels were similar in the two groups. NK1- and NK2-receptor mRNA expression was increased twofold in smokers without airflow obstruction compared with nonsmokers, whereas NK1-receptor mRNA expression was significantly lower in patients with chronic obstructive pulmonary disease compared with smoking controls. In situ hybridization indicated NK1-receptor mRNA was expressed in submucosal glands and airway epithelial cells, whereas NK2-receptor and NK3-receptor mRNA were not detected. These observations have implications for the pathophysiology and treatment of both asthma and tobacco smoke-induced airway inflammation.

UI MeSH Term Description Entries
D008173 Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent. Obstructive Lung Diseases,Obstructive Pulmonary Diseases,Lung Disease, Obstructive,Obstructive Lung Disease,Obstructive Pulmonary Disease,Pulmonary Disease, Obstructive,Pulmonary Diseases, Obstructive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D001254 Astrocytoma Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082) Astrocytoma, Subependymal Giant Cell,Glioma, Astrocytic,Oligoastrocytoma, Mixed,Pleomorphic Xanthoastrocytomas,Anaplastic Astrocytoma,Astrocytoma, Grade I,Astrocytoma, Grade II,Astrocytoma, Grade III,Astrocytoma, Protoplasmic,Astroglioma,Cerebral Astrocytoma,Childhood Cerebral Astrocytoma,Fibrillary Astrocytoma,Gemistocytic Astrocytoma,Intracranial Astrocytoma,Juvenile Pilocytic Astrocytoma,Pilocytic Astrocytoma,Subependymal Giant Cell Astrocytoma,Anaplastic Astrocytomas,Astrocytic Glioma,Astrocytic Gliomas,Astrocytoma, Anaplastic,Astrocytoma, Cerebral,Astrocytoma, Childhood Cerebral,Astrocytoma, Fibrillary,Astrocytoma, Gemistocytic,Astrocytoma, Intracranial,Astrocytoma, Juvenile Pilocytic,Astrocytoma, Pilocytic,Astrocytomas,Astrocytomas, Grade III,Astrogliomas,Cerebral Astrocytoma, Childhood,Cerebral Astrocytomas,Childhood Cerebral Astrocytomas,Fibrillary Astrocytomas,Gemistocytic Astrocytomas,Gliomas, Astrocytic,Grade I Astrocytoma,Grade I Astrocytomas,Grade II Astrocytoma,Grade II Astrocytomas,Grade III Astrocytoma,Grade III Astrocytomas,Intracranial Astrocytomas,Juvenile Pilocytic Astrocytomas,Mixed Oligoastrocytoma,Mixed Oligoastrocytomas,Pilocytic Astrocytoma, Juvenile,Pilocytic Astrocytomas,Pleomorphic Xanthoastrocytoma,Protoplasmic Astrocytoma,Protoplasmic Astrocytomas,Xanthoastrocytoma, Pleomorphic
D012260 Ribonucleases Enzymes that catalyze the hydrolysis of ester bonds within RNA. EC 3.1.-. Nucleases, RNA,RNase,Acid Ribonuclease,Alkaline Ribonuclease,Ribonuclease,RNA Nucleases,Ribonuclease, Acid,Ribonuclease, Alkaline

Related Publications

T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
Hybrid peptides having mixed substance P (NK1), neurokinin A (NK2) and bradykinin (BK2) antagonist properties.
June 1996, Immunopharmacology,
T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
Stable expression of high affinity NK1 (substance P) and NK2 (neurokinin A) receptors but low affinity NK3 (neurokinin B) receptors in transfected CHO cells.
January 1992, FEBS letters,
T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity.
July 1992, The Journal of pharmacology and experimental therapeutics,
T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
Pregnancy-induced changes in substance P and neurokinin 1 receptor (NK1-R) expression in the rat uterus.
October 2003, Reproduction (Cambridge, England),
T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
Preprotachykinin-A and substance P receptor (NK1) gene expression in rat astrocytes in vitro.
December 1994, Neuroscience letters,
T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
June 1997, Canadian journal of physiology and pharmacology,
T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
Substance P and neurokinin-1 receptor expression by intrinsic airway neurons in the rat.
February 2000, American journal of physiology. Lung cellular and molecular physiology,
T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
Substance P receptor (NK1) gene expression in synovial tissue in rheumatoid arthritis and osteoarthritis.
January 1998, Scandinavian journal of rheumatology,
T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine.
November 2000, The American journal of pathology,
T R Bai, and D Zhou, and T Weir, and B Walker, and R Hegele, and S Hayashi, and K McKay, and G P Bondy, and T Fong
Postnatal development of NK1, NK2, and NK3 neurokinin receptors expression in the rat retina.
October 1999, Brain research. Developmental brain research,
Copied contents to your clipboard!